Indications for Paxlovid
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Not Indicated0–0
- Contraindicated1–1
- Standard Dose2–2
- Reduced Dose3–3
The Indications for Paxlovid calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age over 12. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Aids in determining if Paxlovid (nirmatrelvir boosted with ritonavir) is appropriate therapy in an adult COVID-19 positive patient. Paxlovid is an oral antiviral treatment authorized for mild-to-moderate COVID-19 in patients at high risk for progression to severe COVID-19, including hospitalization or death. The tool evaluates eligibility based on FDA guidelines including age, weight, symptom duration, disease severity, kidney function, high-risk conditions, and potential contraindications. Proper patient selection is crucial as the medication must be started within 5 days of symptom onset and has significant drug interactions requiring careful evaluation. The assessment helps clinicians systematically determine appropriate candidates for this time-sensitive antiviral therapy.
Clinical Indication
The Indications for Paxlovid is indicated for bedside clinical practice to support Aids in determining if Paxlovid (nirmatrelvir boosted with ritonavir) is appropriate therapy in an adult COVID-19 positive patient. Paxlovid is an oral antiviral treatment authorized for mild-to-moderate COVID-19 in patients at high risk for progression to severe COVID-19, including hospitalization or death. The tool evaluates eligibility based on FDA guidelines including age, weight, symptom duration, disease severity, kidney function, high-risk conditions, and potential contraindications. Proper patient selection is crucial as the medication must be started within 5 days of symptom onset and has significant drug interactions requiring careful evaluation. The assessment helps clinicians systematically determine appropriate candidates for this time-sensitive antiviral therapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation. Clinical exclusion: Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²).
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials. Guideline pearl: Not recommended for patients already hospitalized due to COVID-19.
Eligibility = All basic criteria met (age >12, weight >40kg, mild-moderate disease, ≤5 days symptoms, eGFR >30, no severe hepatic impairment) AND at least one high-risk factor AND no significant contraindications
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_over_12 | string | Yes | Patient age >12 years. Paxlovid is FDA-approved for patients 12 years and older with appropriate weight and risk factors |
| weight_over_40kg | string | Yes | Patient weight >40 kg (approximately 88 lbs). Minimum weight requirement for safe dosing in pediatric/adolescent patients |
| mild_moderate_covid | string | Yes | Mild to moderate COVID-19 disease severity. Excludes patients with severe COVID-19 requiring hospitalization or oxygen therapy |
| symptom_onset_5_days | string | Yes | Symptom onset ≤5 days. Critical timing requirement - Paxlovid must be initiated within 5 days of COVID-19 symptom onset for efficacy |
| egfr_over_30 | string | Yes | Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m². Severe renal impairment (eGFR <30) is a contraindication |
| no_severe_hepatic_impairment | string | Yes | No severe hepatic impairment (Child-Pugh Class C). Severe liver dysfunction affects drug metabolism and safety |
| age_over_50 | string | Yes | Age >50 years. Major risk factor for progression to severe COVID-19, especially patients ≥65 years |
| diabetes | string | Yes | Diabetes mellitus (Type 1 or Type 2). High-risk condition for severe COVID-19 complications and hospitalization |
| heart_disease | string | Yes | Cardiovascular disease including coronary artery disease, heart failure, cardiomyopathy, or congenital heart disease |
| lung_disease | string | Yes | Chronic lung disease including asthma, COPD, pulmonary fibrosis, or other chronic respiratory conditions |
| obesity | string | Yes | Obesity defined as BMI ≥30 kg/m² or BMI ≥25 kg/m² in adults of Asian descent. Significant risk factor for severe COVID-19 |
| immunocompromised | string | Yes | Immunocompromised state due to disease or medications (cancer, organ transplant, immunosuppressive therapy, HIV, primary immunodeficiency) |
| pregnancy | string | Yes | Current pregnancy. Pregnancy increases risk for severe COVID-19 and adverse pregnancy outcomes |
| unvaccinated_or_not_current | string | Yes | Unvaccinated against COVID-19 or not up to date with COVID-19 vaccines according to CDC recommendations |
| other_high_risk_condition | string | Yes | Other high-risk conditions including cancer, chronic kidney disease, chronic liver disease, neurological conditions, substance use disorders, or other conditions per CDC high-risk list |
| significant_drug_interactions | string | Yes | Significant drug interactions with ritonavir component. Ritonavir is a strong CYP3A4 inhibitor with potential for serious drug-drug interactions |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Not Indicated | Paxlovid not recommended |
| 1–1 | Contraindicated | Paxlovid contraindicated |
| 2–2 | Standard Dose | Paxlovid indicated - standard dose |
| 3–3 | Reduced Dose | Paxlovid indicated - reduced dose |
Evidence-Based References (EBM)
- U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. Updated May 2023.
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408. doi: 10.1056/NEJMoa2118542.DOI: 10.1056/NEJMoa2118542
- Centers for Disease Control and Prevention. Clinical Care Guidance: Oral Antiviral Treatment for COVID-19. Updated 2023.
- NIH COVID-19 Treatment Guidelines Panel. Ritonavir-Boosted Nirmatrelvir (Paxlovid). Updated 2023.